HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on LENZ Therapeutics (NASDAQ:LENZ) and maintained a price target of $38.
August 15, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on LENZ Therapeutics and maintained a price target of $38.
The reiteration of a Buy rating and the maintenance of a $38 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100